Onconetix, Inc. is a commercial stage biotechnology company, which engages in the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The company is headquartered in Cincinnati, Ohio and currently employs 5 full-time employees. The company went IPO on 2022-02-18. The firm owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.
6명의 애널리스트가 ONCO에 대해 제공한 주식 평가를 기반으로 May 01, 2024에 업데이트됨
Sell
Strong buy
0
Buy
0
Hold
3
Sell
1
Strong sell
2
Based on comprehensive analyst evaluations, we have synthesized critical insights from expert assessments to outline a cautious outlook for ONCO. Analysts note deteriorating fundamentals and challenging market sentiment, indicating potential downside risks in the near term. Following this expert analysis, we adopt a bearish stance on this stock. Our conclusion: ONCO is a Sell candidate.
ONCO stock price ended at $1.65 on 목요일, after rising 3.12%
On the latest trading day Jan 22, 2026, the stock price of ONCO rose by 3.12%, climbing from $1.73 to $1.65. During the session, the stock saw a volatility of 16.56%, with prices oscillating between a daily low of $1.51 and a high of $1.76. Notably, trading volume dropped by 1.0M shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 1.0M shares were traded, equating to a market value of approximately $2.5M.
ONCO 기술적 시그널
기술적 시그널 요약
구매 신호 3
중립 신호 2
매도 신호 2
Strong Sell
Sell
Neutral
Buy
Strong Buy
ONCO은 현재 3개의 매수 신호와 2개의 매도 신호를 보이고 있습니다. 이 주식은 12:00 AM 이후로 상승 추세 상태에 있으며, 이 기간 동안 총 가격 변동률은 3.12%입니다. 전반적으로 기술적 지표들은 중기적으로 Buy 전망을 나타내고 있습니다.
ONCO에 대한 강세/약세 신호
이동평균, RSI, MACD, 거래량 등 핵심 지표를 분석하여 ONCO 의 강세/약세 시그널을 생성합니다. 이 인사이트를 활용해 더 현명한 투자 결정을 내리세요.